# RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

> **NCT04620655** · NA · UNKNOWN · sponsor: **Min Xiang** · enrollment: 24 (estimated)

## Conditions studied

- T Acute Lymphoblastic Leukemia
- T-lymphoblastic Lymphoma

## Interventions

- **DRUG:** RD13-01 cell infusion

## Key facts

- **NCT ID:** NCT04620655
- **Lead sponsor:** Min Xiang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-15
- **Primary completion:** 2021-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620655, "RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04620655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*